University of South Dakota Sanford School of Medicine, Vermillion.
Division of Hematology/Oncology, University of South Dakota Sanford School of Medicine, Sioux Falls, SD.
J Immunother. 2018 Sep;41(7):340-342. doi: 10.1097/CJI.0000000000000238.
Checkpoint inhibitor immunotherapy has recently been proven to be an attractive treatment option for a wide variety of malignancies. Nivolumab, an anti-programmed cell death protein-1 antibody, has been proven effective and safe in treating metastatic renal cell carcinoma (RCC) with a clear cell component. We report the case of a patient with high-grade clear cell RCC with rhabdoid features who has achieved a durable complete response with nivolumab therapy after multiple surgical interventions and progression on pazopanib. Genomic evaluation in this case was characterized in part by a PBRM1 variant, similar to the only other described case of RCC with rhabdoid features obtaining a complete response to nivolumab. This case supports the potential utility of checkpoint inhibitors in aggressive, rare subtypes of RCC where there are limited options for therapy.
检查点抑制剂免疫疗法最近已被证明是治疗多种恶性肿瘤的一种有吸引力的治疗选择。纳武利尤单抗是一种抗程序性死亡蛋白-1（PD-1）抗体，已被证明在治疗具有透明细胞成分的转移性肾细胞癌（RCC）方面是有效和安全的。我们报告了一例高级别透明细胞 RCC 伴横纹肌样特征的患者，在多次手术干预和帕唑帕尼进展后，纳武利尤单抗治疗后获得持久完全缓解。该病例的基因组评估部分表现为 PBRM1 变异，与唯一另一例描述的具有横纹肌样特征的 RCC 对纳武利尤单抗完全缓解的病例相似。该病例支持检查点抑制剂在治疗治疗选择有限的侵袭性、罕见的 RCC 亚型中的潜在效用。
